Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Aug;36(8):1589–1595. doi: 10.1128/aac.36.8.1589

Resistance of herpesviruses to antiviral drugs.

P A Chatis 1, C S Crumpacker 1
PMCID: PMC191999  PMID: 1416838

Full text

PDF
1589

Images in this article

1590Image
on p.1590

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balfour H. H., Jr Resistance of herpes simplex to acyclovir. Ann Intern Med. 1983 Mar;98(3):404–406. doi: 10.7326/0003-4819-98-3-404. [DOI] [PubMed] [Google Scholar]
  2. Bean B., Fletcher C., Englund J., Lehrman S. N., Ellis M. N. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. Diagn Microbiol Infect Dis. 1987 Jul;7(3):199–204. doi: 10.1016/0732-8893(87)90005-8. [DOI] [PubMed] [Google Scholar]
  3. Birch C. J., Tachedjian G., Doherty R. R., Hayes K., Gust I. D. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis. 1990 Sep;162(3):731–734. doi: 10.1093/infdis/162.3.731. [DOI] [PubMed] [Google Scholar]
  4. Biron K. K., Fyfe J. A., Stanat S. C., Leslie L. K., Sorrell J. B., Lambe C. U., Coen D. M. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8769–8773. doi: 10.1073/pnas.83.22.8769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Biron K. K., Stanat S. C., Sorrell J. B., Fyfe J. A., Keller P. M., Lambe C. U., Nelson D. J. Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2473–2477. doi: 10.1073/pnas.82.8.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burns W. H., Saral R., Santos G. W., Laskin O. L., Lietman P. S., McLaren C., Barry D. W. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet. 1982 Feb 20;1(8269):421–423. doi: 10.1016/s0140-6736(82)91620-8. [DOI] [PubMed] [Google Scholar]
  7. Chatis P. A., Crumpacker C. S. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology. 1991 Feb;180(2):793–797. doi: 10.1016/0042-6822(91)90093-q. [DOI] [PubMed] [Google Scholar]
  8. Christophers J., Sutton R. N. Characterisation of acyclovir-resistant and -sensitive clinical herpes simplex virus isolates from an immunocompromised patient. J Antimicrob Chemother. 1987 Sep;20(3):389–398. doi: 10.1093/jac/20.3.389. [DOI] [PubMed] [Google Scholar]
  9. Coen D. M., Kosz-Vnenchak M., Jacobson J. G., Leib D. A., Bogard C. L., Schaffer P. A., Tyler K. L., Knipe D. M. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4736–4740. doi: 10.1073/pnas.86.12.4736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Collins P., Larder B. A., Oliver N. M., Kemp S., Smith I. W., Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol. 1989 Feb;70(Pt 2):375–382. doi: 10.1099/0022-1317-70-2-375. [DOI] [PubMed] [Google Scholar]
  11. Crumpacker C. S., Kowalsky P. N., Oliver S. A., Schnipper L. E., Field A. K. Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1556–1560. doi: 10.1073/pnas.81.5.1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Crumpacker C. S., Schnipper L. E., Marlowe S. I., Kowalsky P. N., Hershey B. J., Levin M. J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982 Feb 11;306(6):343–346. doi: 10.1056/NEJM198202113060606. [DOI] [PubMed] [Google Scholar]
  13. Darby G., Field H. J., Salisbury S. A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81–83. doi: 10.1038/289081a0. [DOI] [PubMed] [Google Scholar]
  14. Dorsky D. I., Crumpacker C. S. Drugs five years later: acyclovir. Ann Intern Med. 1987 Dec;107(6):859–874. doi: 10.7326/0003-4819-107-6-859. [DOI] [PubMed] [Google Scholar]
  15. Dorsky D. I., Crumpacker C. S. Site-specific mutagenesis of a highly conserved region of the herpes simplex virus type 1 DNA polymerase gene. J Virol. 1990 Mar;64(3):1394–1397. doi: 10.1128/jvi.64.3.1394-1397.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Drew W. L., Miner R. C., Busch D. F., Follansbee S. E., Gullett J., Mehalko S. G., Gordon S. M., Owen W. F., Jr, Matthews T. R., Buhles W. C. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991 Apr;163(4):716–719. doi: 10.1093/infdis/163.4.716. [DOI] [PubMed] [Google Scholar]
  17. Efstathiou S., Kemp S., Darby G., Minson A. C. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol. 1989 Apr;70(Pt 4):869–879. doi: 10.1099/0022-1317-70-4-869. [DOI] [PubMed] [Google Scholar]
  18. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ellis M. N., Keller P. M., Fyfe J. A., Martin J. L., Rooney J. F., Straus S. E., Lehrman S. N., Barry D. W. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother. 1987 Jul;31(7):1117–1125. doi: 10.1128/aac.31.7.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Englund J. A., Zimmerman M. E., Swierkosz E. M., Goodman J. L., Scholl D. R., Balfour H. H., Jr Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med. 1990 Mar 15;112(6):416–422. doi: 10.7326/0003-4819-76-3-112-6-416. [DOI] [PubMed] [Google Scholar]
  21. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jr, Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989 Feb 2;320(5):289–293. doi: 10.1056/NEJM198902023200505. [DOI] [PubMed] [Google Scholar]
  22. Eriksson B., Larsson A., Helgstrand E., Johansson N. G., Oberg B. Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim Biophys Acta. 1980 Mar 28;607(1):53–64. doi: 10.1016/0005-2787(80)90220-8. [DOI] [PubMed] [Google Scholar]
  23. Erlich K. S., Mills J., Chatis P., Mertz G. J., Busch D. F., Follansbee S. E., Grant R. M., Crumpacker C. S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):293–296. doi: 10.1056/NEJM198902023200506. [DOI] [PubMed] [Google Scholar]
  24. Field H. J., Coen D. M. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol. 1986 Oct;60(1):286–289. doi: 10.1128/jvi.60.1.286-289.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Field H. J., Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (Lond) 1978 Oct;81(2):267–277. doi: 10.1017/s0022172400025109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Frank K. B., Cheng Y. C. Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin, phosphonoformate, and acyclic nucleoside triphosphates. Antimicrob Agents Chemother. 1985 Apr;27(4):445–448. doi: 10.1128/aac.27.4.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Furman P. A., St Clair M. H., Fyfe J. A., Rideout J. L., Keller P. M., Elion G. B. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol. 1979 Oct;32(1):72–77. doi: 10.1128/jvi.32.1.72-77.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Furman P. A., St Clair M. H., Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem. 1984 Aug 10;259(15):9575–9579. [PubMed] [Google Scholar]
  29. Gateley A., Gander R. M., Johnson P. C., Kit S., Otsuka H., Kohl S. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis. 1990 Apr;161(4):711–715. doi: 10.1093/infdis/161.4.711. [DOI] [PubMed] [Google Scholar]
  30. Graham D., Larder B. A., Inglis M. M. Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J Gen Virol. 1986 Apr;67(Pt 4):753–758. doi: 10.1099/0022-1317-67-4-753. [DOI] [PubMed] [Google Scholar]
  31. Grossberg H. S., Bonnem E. M., Buhles W. C., Jr GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS. N Engl J Med. 1989 Jun 8;320(23):1560–1560. doi: 10.1056/NEJM198906083202317. [DOI] [PubMed] [Google Scholar]
  32. Gulick R. M., Heath-Chiozzi M., Crumpacker C. S. Varicella-zoster virus disease in patients with human immunodeficiency virus infection. Arch Dermatol. 1990 Aug;126(8):1086–1088. [PubMed] [Google Scholar]
  33. Haffey M. L., Novotny J., Bruccoleri R. E., Carroll R. D., Stevens J. T., Matthews J. T. Structure-function studies of the herpes simplex virus type 1 DNA polymerase. J Virol. 1990 Oct;64(10):5008–5018. doi: 10.1128/jvi.64.10.5008-5018.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Haffey M. L., Stevens J. T., Terry B. J., Dorsky D. I., Crumpacker C. S., Wietstock S. M., Ruyechan W. T., Field A. K. Expression of herpes simplex virus type 1 DNA polymerase in Saccharomyces cerevisiae and detection of virus-specific enzyme activity in cell-free lysates. J Virol. 1988 Dec;62(12):4493–4498. doi: 10.1128/jvi.62.12.4493-4498.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hardy W. D. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr. 1991;4 (Suppl 1):S22–S28. [PubMed] [Google Scholar]
  36. Hwang C. B., Ruffner K. L., Coen D. M. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J Virol. 1992 Mar;66(3):1774–1776. doi: 10.1128/jvi.66.3.1774-1776.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Jacobson M. A., Berger T. G., Fikrig S., Becherer P., Moohr J. W., Stanat S. C., Biron K. K. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Feb 1;112(3):187–191. doi: 10.7326/0003-4819-112-3-187. [DOI] [PubMed] [Google Scholar]
  38. Jacobson M. A., O'Donnell J. J. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. J Acquir Immune Defic Syndr. 1991;4 (Suppl 1):S11–S15. [PubMed] [Google Scholar]
  39. Kit S., Sheppard M., Ichimura H., Nusinoff-Lehrman S., Ellis M. N., Fyfe J. A., Otsuka H. Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir. Antimicrob Agents Chemother. 1987 Oct;31(10):1483–1490. doi: 10.1128/aac.31.10.1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Knopf K. W., Kaufman E. R., Crumpacker C. Physical mapping of drug resistance mutations defines an active center of the herpes simplex virus DNA polymerase enzyme. J Virol. 1981 Sep;39(3):746–757. doi: 10.1128/jvi.39.3.746-757.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Larder B. A., Kemp S. D., Darby G. Related functional domains in virus DNA polymerases. EMBO J. 1987 Jan;6(1):169–175. doi: 10.1002/j.1460-2075.1987.tb04735.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Linnemann C. C., Jr, Biron K. K., Hoppenjans W. G., Solinger A. M. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS. 1990 Jun;4(6):577–579. doi: 10.1097/00002030-199006000-00014. [DOI] [PubMed] [Google Scholar]
  43. Ljungman P., Ellis M. N., Hackman R. C., Shepp D. H., Meyers J. D. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis. 1990 Jul;162(1):244–248. doi: 10.1093/infdis/162.1.244. [DOI] [PubMed] [Google Scholar]
  44. Ljungman P., Lönnqvist B., Gahrton G., Ringdén O., Sundqvist V. A., Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis. 1986 May;153(5):840–847. doi: 10.1093/infdis/153.5.840. [DOI] [PubMed] [Google Scholar]
  45. Manischewitz J. F., Quinnan G. V., Jr, Lane H. C., Wittek A. E. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990 Feb;34(2):373–375. doi: 10.1128/aac.34.2.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Marks G. L., Nolan P. E., Erlich K. S., Ellis M. N. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis. 1989 May-Jun;11(3):474–476. doi: 10.1093/clinids/11.3.474. [DOI] [PubMed] [Google Scholar]
  47. Martin J. L., Ellis M. N., Keller P. M., Biron K. K., Lehrman S. N., Barry D. W., Furman P. A. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. Antimicrob Agents Chemother. 1985 Aug;28(2):181–187. doi: 10.1128/aac.28.2.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Matthews J. T., Carroll R. D., Stevens J. T., Haffey M. L. In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme. J Virol. 1989 Nov;63(11):4913–4918. doi: 10.1128/jvi.63.11.4913-4918.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. McLaren C., Chen M. S., Ghazzouli I., Saral R., Burns W. H. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agents Chemother. 1985 Dec;28(6):740–744. doi: 10.1128/aac.28.6.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Miller W. H., Miller R. L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem. 1980 Aug 10;255(15):7204–7207. [PubMed] [Google Scholar]
  51. Norris S. A., Kessler H. A., Fife K. H. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis. 1988 Jan;157(1):209–210. doi: 10.1093/infdis/157.1.209. [DOI] [PubMed] [Google Scholar]
  52. Oliver N. M., Collins P., Van der Meer J., Van't Wout J. W. Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir. Antimicrob Agents Chemother. 1989 May;33(5):635–640. doi: 10.1128/aac.33.5.635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Pahwa S., Biron K., Lim W., Swenson P., Kaplan M. H., Sadick N., Pahwa R. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA. 1988 Nov 18;260(19):2879–2882. [PubMed] [Google Scholar]
  54. Parker A. C., Craig J. I., Collins P., Oliver N., Smith I. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase. Lancet. 1987 Dec 19;2(8573):1461–1461. doi: 10.1016/s0140-6736(87)91157-3. [DOI] [PubMed] [Google Scholar]
  55. Reardon J. E., Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405–7411. [PubMed] [Google Scholar]
  56. Sacks S. L., Wanklin R. J., Reece D. E., Hicks K. A., Tyler K. L., Coen D. M. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med. 1989 Dec 1;111(11):893–899. doi: 10.7326/0003-4819-111-11-893. [DOI] [PubMed] [Google Scholar]
  57. Safrin S., Assaykeen T., Follansbee S., Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis. 1990 Jun;161(6):1078–1084. doi: 10.1093/infdis/161.6.1078. [DOI] [PubMed] [Google Scholar]
  58. Safrin S., Berger T. G., Gilson I., Wolfe P. R., Wofsy C. B., Mills J., Biron K. K. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991 Jul 1;115(1):19–21. doi: 10.7326/0003-4819-115-1-19. [DOI] [PubMed] [Google Scholar]
  59. Safrin S., Crumpacker C., Chatis P., Davis R., Hafner R., Rush J., Kessler H. A., Landry B., Mills J. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1991 Aug 22;325(8):551–555. doi: 10.1056/NEJM199108223250805. [DOI] [PubMed] [Google Scholar]
  60. Schinazi R. F. Drug combinations for treatment of mice infected with acyclovir-resistant herpes simplex virus. Antimicrob Agents Chemother. 1987 Mar;31(3):477–479. doi: 10.1128/aac.31.3.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Schinazi R. F., del Bene V., Scott R. T., Dudley-Thorpe J. B. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):127–134. doi: 10.1093/jac/18.supplement_b.127. [DOI] [PubMed] [Google Scholar]
  62. Schnipper L. E., Crumpacker C. S. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2270–2273. doi: 10.1073/pnas.77.4.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Shepp D. H., Dandliker P. S., Meyers J. D. Current therapy of varicella zoster virus infection in immunocompromised patients. A comparison of acyclovir and vidarabine. Am J Med. 1988 Aug 29;85(2A):96–98. [PubMed] [Google Scholar]
  64. Shigeta S., Mori S., Yokota T., Konno K., De Clercq E. Characterization of a varicella-zoster virus variant with altered thymidine kinase activity. Antimicrob Agents Chemother. 1986 Jun;29(6):1053–1058. doi: 10.1128/aac.29.6.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Sibrack C. D., Gutman L. T., Wilfert C. M., McLaren C., St Clair M. H., Keller P. M., Barry D. W. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis. 1982 Nov;146(5):673–682. doi: 10.1093/infdis/146.5.673. [DOI] [PubMed] [Google Scholar]
  66. Taylor E. W., Jaakkola J. A transposition of the reverse transcriptase gene reveals unexpected structural homology to E. coli DNA polymerase I. Genetica. 1991;84(2):77–86. doi: 10.1007/BF00116546. [DOI] [PubMed] [Google Scholar]
  67. Tenser R. B. Intracerebral inoculation of newborn and adult mice with thymidine kinase-deficient mutants of herpes simplex virus type 1. J Infect Dis. 1983 May;147(5):956–956. doi: 10.1093/infdis/147.5.956. [DOI] [PubMed] [Google Scholar]
  68. Tenser R. B., Jones J. C., Ressel S. J. Acute and latent infection by thymidine kinase mutants of herpes simplex virus type 2. J Infect Dis. 1985 Mar;151(3):548–550. doi: 10.1093/infdis/151.3.548. [DOI] [PubMed] [Google Scholar]
  69. Tenser R. B., Miller R. L., Rapp F. Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus. Science. 1979 Aug 31;205(4409):915–917. doi: 10.1126/science.224454. [DOI] [PubMed] [Google Scholar]
  70. Vinckier F., Boogaerts M., De Clerck D., De Clercq E. Chronic herpetic infection in an immunocompromised patient: report of a case. J Oral Maxillofac Surg. 1987 Aug;45(8):723–728. doi: 10.1016/0278-2391(87)90320-x. [DOI] [PubMed] [Google Scholar]
  71. Wade J. C., McLaren C., Meyers J. D. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis. 1983 Dec;148(6):1077–1082. doi: 10.1093/infdis/148.6.1077. [DOI] [PubMed] [Google Scholar]
  72. Walmsley S. L., Chew E., Read S. E., Vellend H., Salit I., Rachlis A., Fanning M. M. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). J Infect Dis. 1988 Mar;157(3):569–572. doi: 10.1093/infdis/157.3.569. [DOI] [PubMed] [Google Scholar]
  73. Wilcox C. L., Crnic L. S., Pizer L. I. Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant. Virology. 1992 Mar;187(1):348–352. doi: 10.1016/0042-6822(92)90326-k. [DOI] [PubMed] [Google Scholar]
  74. Wong S. W., Wahl A. F., Yuan P. M., Arai N., Pearson B. E., Arai K., Korn D., Hunkapiller M. W., Wang T. S. Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases. EMBO J. 1988 Jan;7(1):37–47. doi: 10.1002/j.1460-2075.1988.tb02781.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES